Combining Targeted Therapy With Checkpoint Blockade for the Treatment of Melanoma

In an interview with Targeted Oncology, Sergio A. Giralt, MD, discussed the evolving role of transplant in myelodysplastic syndromes.

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Fianlimab combined with cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma, regardless of LAG-3 or PD-L1 expression.

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Long-term findings from KEYNOTE-006, a phase 3 trial, support pembrolizumab as a standard-of-care for patients with advanced melanoma.

Nivolumab, alone or with ipilimumab, significantly improved 10-year overall and melanoma-specific survival vs ipilimumab alone in advanced melanoma, according to final phase 3 CheckMate 067 trial data.